Anuh Pharma receives Certificate of Suitability from European regulator for Sulfadimethoxine
NSE-BSE listed bulk drug company – Anuh Pharma has received Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for Sulfadimethoxine.
This approval reinforces Anuh Pharma’s commitment to delivering high-quality Active Pharmaceutical Ingredients that adhere to the most stringent global regulatory standards.
The CEP for Sulfadimethoxine will enable expanded access to regulated markets and support our customers with enhanced reliability, compliance, and supply security.
Sulfadimethoxine is a bacteriostatic antibiotic that works by inhibiting bacteria from synthesizing folic acid, an essential compound for their growth and survival. It achieves this by acting as a competitive inhibitor against para-aminobenzoic acid (PABA).
This drug is widely approved and used in dogs, cats, small mammals, reptiles, and livestock. It is the most common medication prescribed for the treatment of coccidiosis (an intestinal parasite infection) in dogs. It is also effective against various respiratory, urinary tract, enteric, and soft tissue bacterial infections.
Above views are of the author and not of the website kindly read disclaimer
